PT - JOURNAL ARTICLE AU - DAN NORDSTRÖM AU - ANN KNIGHT AU - REIJO LUUKKAINEN AU - RONALD van VOLLENHOVEN AU - VAPPU RANTALAIHO AU - ANNA KAJALAINEN AU - JOHAN G. BRUN AU - ANNE PROVEN AU - LOTTA LJUNG AU - HANNU KAUTIAINEN AU - TOM PETTERSSON TI - Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still’s Disease. An Open, Randomized, Multicenter Study AID - 10.3899/jrheum.111549 DP - 2012 Oct 01 TA - The Journal of Rheumatology PG - 2008--2011 VI - 39 IP - 10 4099 - http://www.jrheum.org/content/39/10/2008.short 4100 - http://www.jrheum.org/content/39/10/2008.full SO - J Rheumatol2012 Oct 01; 39 AB - Objective. To study the efficacy of anakinra versus disease-modifying antirheumatic drugs (DMARD) in refractory adult-onset Still’s disease (AOSD). Methods. In a 24-week study, 22 patients with AOSD taking prednisolone ≥ 10 mg/day received anakinra (n = 12) or DMARD (n = 10). The primary endpoint was achievement of remission. Results. At 8 and 24 weeks, 7/12 and 6/12 receiving anakinra and 5/10 and 2/10 receiving DMARD achieved remission. Anakinra induced greater improvement in physical health measured by Medical Outcomes Study Short-Form 36 (SF-36; p < 0.011). During an open-label extension (OLE) of 28 weeks, 7/14 patients taking anakinra and 2/3 taking DMARD were in remission. Conclusion. Anakinra induced more beneficial responses than DMARD in patients with AOSD and was favored in the OLE phase. (ClinicalTrials.gov Protocol Registration NCT01033656).